A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Atherosclerosis
- Amputation
- Arterial Occlusive Disease
- Arteriosclerosis
- Cardiovascular Disease
- Ischemia
- Orthopedic Procedures
- Pathologic Processes
- Peripheral Arterial Disease
- Peripheral Vascular Disease
- Vascular Disease
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 40 years and 90 years
- Gender
- Both males and females
Description
This is a phase I single center open label trial study that will enroll sixteen patients requiring semi-elective lower extremity major amputation within a 30 day period for non-infectious complications related to critical limb ischemia (CLI). After enrollment patients will be scheduled for amputatio...
This is a phase I single center open label trial study that will enroll sixteen patients requiring semi-elective lower extremity major amputation within a 30 day period for non-infectious complications related to critical limb ischemia (CLI). After enrollment patients will be scheduled for amputation 7 days after MSC administration. The investigational treatment uses allogeneic bone marrow derived mesenchymal stem cells at the point of care. Allogeneic MSCs will be injected in the thigh muscles and the gastrocnemius muscle (for below knee amputation only) of sixteen patients undergoing major amputation. Through a review of treatment related adverse events over 6 months we will test the hypothesis that allogeneic MSCs do not result in significant cardiovascular, respiratory, or infectious treatment related adverse events. Through an exploratory investigation we will assess the efficacy of MSCs in promoting freedom from gangrene, revision of amputation, and death after major amputation.
Tracking Information
- NCT #
- NCT02685098
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Michael P Murphy, MD Indiana University